Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Merck is a global pharmaceutical company with a concentrated portfolio anchored by Keytruda, the world's leading cancer immunotherapy generating approximately $25B+ annually (roughly 40% of total revenue). The company operates across oncology, vaccines (Gardasil for HPV), hospital acute care, and animal health, with significant R&D investments ($13B+ annually) focused on next-generation oncology and cardiometabolic therapies. Competitive position depends on maintaining Keytruda's dominance through label expansions while successfully commercializing pipeline assets before the 2028 US patent cliff.
Merck operates a patent-protected pharmaceutical model with exceptional pricing power in oncology and vaccines. Keytruda commands premium pricing ($150K+ annual cost per patient) due to superior efficacy data and first-mover advantage in PD-1 inhibition. The company leverages global regulatory approvals and reimbursement relationships to maximize geographic penetration. Gross margins exceeding 80% reflect minimal manufacturing costs relative to R&D-driven value creation. Revenue durability depends on continuous clinical trial success to expand approved indications and delay generic competition. The 41% operating margin demonstrates efficient commercialization infrastructure despite $13B+ annual R&D spend.
Keytruda clinical trial readouts and label expansion approvals (particularly in earlier-stage cancer settings and combination therapies)
Pipeline progress for post-Keytruda growth drivers including MK-0616 (PCSK9 inhibitor), sotatercept (pulmonary arterial hypertension), and next-generation oncology assets
Gardasil international penetration rates, especially China market access and reimbursement decisions
Patent litigation outcomes and generic entry timelines for major products (Keytruda US exclusivity expires 2028)
M&A activity and business development deals to supplement organic pipeline
Keytruda patent cliff (2028 US exclusivity expiration) represents $25B+ revenue at risk without successful pipeline replacement; biosimilar competition will erode pricing power and market share
Increasing political pressure for drug pricing reform in US (Medicare negotiation provisions in Inflation Reduction Act, potential further legislation) threatens pricing power across portfolio
Regulatory approval risk for pipeline assets - clinical trial failures or delayed approvals could leave revenue gap post-Keytruda patent expiration
Shift toward value-based care and outcomes-based reimbursement models may pressure margins if real-world efficacy data underperforms clinical trials
Oncology competition intensifying from Bristol-Myers Squibb (Opdivo), Roche (Tecentriq), and emerging bispecific antibodies that may offer superior efficacy in specific tumor types
Next-generation cell and gene therapies (CAR-T, TCR-T) could disrupt traditional small molecule and antibody franchises with curative rather than chronic treatment paradigms
Chinese pharmaceutical companies developing biosimilar versions of Keytruda at significantly lower price points for emerging markets
Large pharma competitors (Pfizer, Novartis, AstraZeneca) with deeper pipelines and greater diversification reducing concentration risk
Reported Debt/Equity of 0.00 and Current Ratio of 0.00 suggest incomplete financial data rather than actual zero leverage; typical pharma companies carry moderate debt for tax efficiency
Pension and post-retirement benefit obligations common in legacy pharmaceutical companies can represent multi-billion dollar unfunded liabilities
Contingent liabilities from ongoing patent litigation and potential product liability claims (though insured)
Currency exposure from international operations (~50% of revenue ex-US) creates translation risk, particularly EUR and CNY fluctuations
low - Pharmaceutical demand is highly inelastic, particularly for life-saving oncology treatments and preventative vaccines. Keytruda prescriptions are driven by cancer incidence and clinical guidelines rather than GDP growth. However, elective procedures and animal health products show modest cyclical sensitivity. Emerging market vaccine uptake can be affected by government healthcare budgets during economic downturns.
Rising rates create modest headwinds through higher discount rates applied to long-duration cash flows (Keytruda patent extends to 2028-2033 depending on jurisdiction), compressing valuation multiples. However, Merck's $18B+ annual free cash flow and minimal net debt position ($0.00 D/E ratio reported) insulate operations from financing cost pressures. Rate increases may slow M&A activity by raising acquisition financing costs and hurdle rates for deals.
Minimal - pharmaceutical reimbursement comes primarily from government payers (Medicare, Medicaid, European national health systems) and large commercial insurers with strong credit profiles. Patient out-of-pocket exposure is limited by co-pay assistance programs. Merck maintains investment-grade credit rating with strong cash generation, eliminating refinancing risk.
value and dividend - The stock appeals to investors seeking stable cash flows and dividend income (current yield likely 2.5-3.5% range) with defensive characteristics. The 81.5% gross margin and 28.1% net margin attract quality-focused value investors. However, the 2028 Keytruda patent cliff creates a binary outcome scenario that also draws event-driven and deep value investors betting on successful pipeline execution. Recent 41% six-month return suggests momentum investors have entered on pipeline optimism. The 7.0% FCF yield is attractive for cash flow-focused strategies.
moderate - Large-cap pharmaceutical stocks typically exhibit beta of 0.6-0.8, providing downside protection during market selloffs due to defensive revenue characteristics. However, binary clinical trial outcomes and regulatory decisions create episodic volatility spikes. The 23.6% three-month return indicates recent volatility expansion, likely driven by pipeline news flow. Patent cliff visibility in 2028 may increase volatility as that date approaches if pipeline execution disappoints.
